Data-driven identification of co-morbidities associated with rheumatoid arthritis in a large US health plan claims database

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Petri, Hans ^a   Maldonato, Debra ^b   Robinson, Noah Jamie ^c  

^a ROCHE PRODUCTS LTD   (United Kingdom)

^b Epidemiology and Patient Reported Outcomes   (United States)

^c Building 663   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ANEMIA; ARTHROPATHY; ARTICLE; COMORBIDITY; CUSHING SYNDROME; DATA BASE; DERMATITIS; ECZEMA; FEMALE; HUMAN; IMMUNE DEFICIENCY; MAJOR CLINICAL STUDY; MALE; NATIONAL HEALTH INSURANCE; OSTEOMYELITIS; RHEUMATOID ARTHRITIS; SEDIMENTATION RATE; TUBERCULIN TEST; ADOLESCENT; AGED; COHORT ANALYSIS; HEALTH INSURANCE; HEALTH STATUS; MIDDLE AGED; RETROSPECTIVE STUDY; UNITED STATES;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; COHORT STUDIES; COMORBIDITY; DATABASES AS TOPIC; FEMALE; HEALTH STATUS; HUMANS; INSURANCE, HEALTH; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; UNITED STATES; YOUNG ADULT;

EID: 77958121473     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-247     Document Type: Article

References (25)

1. Post-marketing surveillance: a UK/European perspective. S Gough, Curr Med Res Opin 2005 21 565 70 10.1185/030079905X41426 15899105
2. Cardiovascular safety of drugs not intended for cardiovascular use: need for a new conceptual basis for assessment and approval. JS Borer H Pouleur E Abadie F Follath J Wittes MA Pfeffer B Pitt F Zannad, Eur Heart J 2007 28 1904 9 10.1093/eurheartj/ehm209 17615083
3. A systematic review of NSAIDs withdrawn from the market due to hepatoxicity: lessons learned from the bromfenac experience. L Goldkind L Laine, Pharmacoepidemiol Drug Saf 2006 15 213 220 10.1002/pds.1207 16456879
4. Four years after withdrawal of rofecoxib: where do we stand today? W Jaksch C Dejaco M Schirmer, Rheumatol Int 2008 28 1187 1195 10.1007/s00296-008- 0650-4 18663451
5. Medicines and Healthcare products Regulatory Agency, Good Pharmacovigilance Practice Guide London: Pharmaceutical Press 2009 88 89
6. A to-do list for the new FDA commissioner. S Okie, N Engl J Med 2009 360 1373 1378 10.1056/NEJMp0810755 19287021
7. Adverse event detection in drug development: recommendations and obligations beyond phase 3. JA Berlin SC Glasser SS Ellenberg, Am J Pub Health 2008 98 1366 1371 10.2105/AJPH.2007.124537
8. Frequency of infection in patients with rheumatoid arthritis compared with controls. MF Doran CS Crowson GR Pound M O' Fallon SE Gabriel, Arthr Rheumat 2002-1 46 2287 93 10.1002/art.10524
9. Predictors of infection in rheumatoid arthritis. MF Doran CS Crowson GR Pond, Arthr Rheum 2002-2 46 2294 2300 10.1002/art.10529
10. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort in Sweden, 1964-95. L Björnodal E Baeklund L Yin,, et al. J Rheumatology 2002 29 906 912
11. Cardiovascular morbidity and mortality in women with RA. DH Solomon EW Karlson EB Rimm,, et al. Circulation 2003 107 1303 1307 10.1161/01.CIR. 0000054612.26458.B2 12628952
12. Epidemiology of extra-articular manifestations in rheumatoid arthritis. C Turesson LT Jacobsson, Scand J Rheumatol 2004 33 65 72 10.1080/ 03009740310004621 15163106 (Pubitemid 38437967)
13. All cause mortality and vascular events in RA, Osteoarthritis, or no arthritis in the UK. D Watson T Rhodes H Guess, J Rheumatol 2003 30 1196 1202 12784389
14. Extra-articular manifestations and complications of rheumatoid arthritis. A Young G Koduri, Best Pract Res Clin Rheumatol 2007 21 907 927 10.1016/j.berh.2007.05.007 17870035
15. Health research data for the real world: the Marketscan databases. DM Adamson S Chang LG Hansen, New York: Thompson Healthcare 2008
16. Performing a 1:N Case-Control Match on Propensity Score. LS Parsons, Proceedings of the Twenty-Nineth Annual SAS Users Group International Conference Cary, NC: SAS Institute Inc. 2004
17. Increased incidence of CV disease in RA. C Turesson A Jarenros L Jacobsson, Ann Rheum 2004 63 952 955 10.1136/ard.2003.018101 (Pubitemid 38961920)
18. Extra-articular manifestations and complications of rheumatoid arthritis. A Young G Koduri, Best Pract Res Clin Rheumatol 2007 21 907 927 10.1016/j.berh.2007.05.007 17870035
19. Incidence of clinically manifest ulcers and their complications in patients with rheumatoid arthritis. KS Steen WF Lems J Aertsen D Bezemer BA Dijkmans, Ann Rheum Dis 2001 60 443 447 10.1136/ard.60.5.443 11302864
20. Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis. KS Steen MT Nurmohamed I Visman M Heijerman M Boers BA Dijkmans WF Lems, Ann Rheum Dis 2008 67 256 259 10.1136/ard.2006.068015 17604285
21. Predictors of infection in rheumatoid arthritis. MF Doran CS Crowson GR Pond, Arthr Rheum 2002-2 46 2294 2300 10.1002/art.10529
22. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to TNF-a antagonists. J Curtis N Patkar A Xie,, et al. Arthr& Rheumatism 2007 56 1125 1133
23. Infections in patients with rheumatoid arthritis treated with biologic agents. J Listing A Strangfeld S Kary,, et al. Arthr& Rheumatism 2005 52 3403 3412
24. Clinical assessment of the long-term risk of practure in patients with rheumatoid arthritis. TP Van Staa P Geusens JW Bijlsma HG Leufekens C Cooper, Arthritis Rheum 2006 54 3104 12 10.1002/art.22117 17009229
25. Comorbidities in rheumatoid arthritis. K Michaud F Wolfe, Best Pract Res Clin Pharmacol 2007 21 885 906 10.1016/j.berh.2007.06.002 (Pubitemid 47377810)